glp-1 usage by country Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market 2035 Obesity GLP-1 Market

Understanding GLP-1: The Hormone Behind Effective Weight Loss Injections When it comes to weight loss, the journey can feel overwhelming

Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for treating type 2 diabetes and reducing cardiovascular risk

A patient with an autoimmune disease and digestive issues, for instance, might find that by treating his gut with probiotics, bone broth or collagen and removing gluten and other inflammatory foods from his diet, his body begins to heal, Axe says

The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist

Regulatory context every buyer needs in June 2026: On April 30, 2026, the FDA proposed removing semaglutide and tirzepatide from the 503B outsourcing bulks list - the pathway that enabled large-scale compounding